A randomised, placebo-controlled, double-blind study to investigate the efficacy and safety of rFVIIa as adjunctive therapy for control of bleeding in patients with severe blunt trauma: a re-analysis following the exclusion of early (< 48 hours) deaths

Documents similaires

• Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial
  par: Kluger, Yoram, et autres
  Publié: (2007)
• Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials
  par: Rizoli, Sandro B, et autres
  Publié: (2006)
• Cost-effectiveness analysis of recombinant activated factor VII as adjunctive therapy for bleeding control in severely injured trauma patients in Germany
  par: Rossaint, R, et autres
  Publié: (2006)
• Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
  par: Klitgaard, Thomas, et autres
  Publié: (2006)
• Recombinant activated coagulation factor VII (rFVIIa) as an adjunctive hemostatic therapy in patients with multiple system organ failure and acute upper gastrointestinal bleeding
  par: Milanov, S, et autres
  Publié: (2003)